A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)
Case Comprehensive Cancer Center
Case Comprehensive Cancer Center
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Wake Forest University Health Sciences
University of Nebraska
University of Nebraska
Eastern Cooperative Oncology Group
Massachusetts General Hospital
Mayo Clinic
Memorial Sloan Kettering Cancer Center
Northwestern University
Roswell Park Cancer Institute
Universität des Saarlandes
National Cancer Institute (NCI)
Mayo Clinic
Jonsson Comprehensive Cancer Center
Jonsson Comprehensive Cancer Center
Case Comprehensive Cancer Center
Canadian Cancer Trials Group
Mayo Clinic
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Acrotech Biopharma Inc.
Fred Hutchinson Cancer Center
University of Wisconsin, Madison
National Cancer Institute (NCI)
University of Wisconsin, Madison
Mayo Clinic
Roswell Park Cancer Institute
Mayo Clinic
Roswell Park Cancer Institute
University of Chicago
Takeda
Swiss Cancer Institute
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
M.D. Anderson Cancer Center
Wake Forest University Health Sciences
Wake Forest University Health Sciences
Ohio State University Comprehensive Cancer Center
Virginia Commonwealth University
National Cancer Institute (NCI)
European Organisation for Research and Treatment of Cancer - EORTC
University of California, San Francisco
National Cancer Institute (NCI)
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Wake Forest University Health Sciences
Wake Forest University Health Sciences